Almirall launches Klisyri for actinic keratosis


February 23, 2021

1 min read


Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .



We were unable to process your request. Please try again later. If you continue to have this issue please contact

Back to Healio

Klisyri, a topical treatment for actinic keratosis, has been launched by Almirall following a December approval by the FDA, according to a press release.

Klisyri (tirbanibulin), a novel topical microtubule inhibitor, is indicated for AK treatment on the face and scalp.

In two phase 3 clinical studies, Klisyri achieved significantly higher rates of complete AK clearance compared with vehicle and met its secondary endpoint of partial skin clearance compared with vehicle.

“The incidence of actinic keratosis has been increasing, including in younger adults,” Ayman Grada, MD, head of R&D and medical affairs at Almirall U.S., said in the release. “Patients may prefer a treatment option with a short duration and proven safety and tolerability profile…


Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.